ResMed (RMD) Tops Q2 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight
January 25, 2019 7:10 AM ESTJPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.
Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More
Goldman Sachs Downgrades ResMed (RMD:AU) (RMD) to Neutral
January 25, 2019 7:01 AM ESTGoldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).
Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More
Deutsche Bank Downgrades ResMed (RMD) to Hold
January 23, 2019 8:42 AM ESTDeutsche Bank downgraded ResMed (NYSE: RMD) from Buy to Hold.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $117.69 yesterday.
... More